Facebook Linkedin Twitter
Inside Precision Medicine YTHDF2 in B Cell Malignancies: A New Pathway to Enhanced Immunotherapy

Acute lymphoblastic leukemia

Close up image of a lymphoma cancer cell that can be targeted with CAR T-cell therapy
Oncology

YTHDF2 in B Cell Malignancies: A New Pathway to Enhanced Immunotherapy

Alice McCarthy
0
Tom and Emily whitehead
Multimedia

Not All Precision Medicine Heroes Wear Lab Coats

Jonathan D. Grinstein, PhD
0
Destruction of leukaemia cell in blood cancer
Molecular Dx

Certain Pediatric Leukemia Subtypes Can Have Good Outcomes Even with Low-Intensity Therapy 

0
Acute lymphoblastic leukaemia, illustration
News & Features

Non-Coding DNA Found to Be Major Driver of T-Lineage Acute Lymphoblastic Leukemia

0
Blood Testing
News & Features

Minimal Disease, Maximum Benefit

Chris Anderson
0
Acute lymphoblastic leukaemia, illustration
News & Features

B-Cell Development Vulnerability in Leukemia Suggests Novel Combination Therapy

0
cancer development
News & Features

Can Immunotherapy be Democratized?

Mike May, PhD
0
antibodies
News & Features

Charging to the Frontline

Chris Anderson
0
CAR T cell immunotherapy, illustration
News & Features

Autolus Confirms Positive Phase II Findings for Obe-cel CAR T-Cell Therapy

0
Acute lymphoblastic leukemia ALL-L2 blood smear under light microscopy
News & Features

Immunotherapy Substantially Improves Outcomes for Babies with Leukemia

Laura Cowen
0
123Page 1 of 3

Related Content

Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine